Literature DB >> 9614870

Different HTLV-I neutralization patterns among sera of patients infected with cosmopolitan HTLV-I.

S Blanchard1, T Astier-Gin, D Moynet, E Edouard, B Guillemain.   

Abstract

To determine if sequence variations observed in cosmopolitan HTLV-I interfered with viral recognition by neutralizing antibodies, we evaluated the neutralization potential of sera from persons infected by HTLV-I of this clade selected for amino acid changes in their eny glycoproteins. Each serum was used to neutralize three previously described HTLV-I isolates, 2060, 2072, and 1010, that possess amino acid env sequences differing at several positions, one of them being located in the immunodominant and neutralizable domain (aa 187-199). The results obtained in syncytia and/or reporter gene inhibition assays showed that the neutralization pattern of the sera clearly differed and could be classified in three categories. Five sera completely neutralized the three viruses with an equivalent titer, two sera gave a maximum inhibition, with higher ID50 on the 2072 virus than on the 2060 or 1010 viruses, and three sera had a stronger neutralization potential toward the 1010 virus than toward the 2060 virus. One of these sera partially neutralized the virus produced by 2072 cells, whereas neutralizing antibodies in the other two recognized the neutralizable epitopes on the 1010 or 2072 viruses equally well. Identification of amino acid sequences involved in induction of neutralizing antibodies with different recognition capacities could help identify new neutralizable epitopes of HTLV-I envelope glycoproteins and to better define the component(s) of an effective vaccine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614870     DOI: 10.1006/viro.1998.9139

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  3 in total

1.  High variability of HTLV-I in a remote population of Gabon as compared to that of a similar population of French Guiana.

Authors:  D Moynet; J F Pouliquen; D Londos-Gagliardi; R P Buigues; J F Moreau; I Bedjabaga; M C Georges; A Talarmin; M Joubert; H Fleury; P Vincendeau; B Guillemain
Journal:  Virus Genes       Date:  2001-12       Impact factor: 2.332

2.  Amino acid changes at positions 173 and 187 in the human T-cell leukemia virus type 1 surface glycoprotein induce specific neutralizing antibodies.

Authors:  S Blanchard; T Astier-Gin; B Tallet; D Moynet; D Londos-Gagliardi; B Guillemain
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

3.  Conservation of a Neutralization Epitope of Human T-cell Leukemia Virus Type 1 (HTLV-1) among Currently Endemic Clinical Isolates in Okinawa, Japan.

Authors:  Mariko Mizuguchi; Yoshiaki Takahashi; Reiko Tanaka; Takuya Fukushima; Yuetsu Tanaka
Journal:  Pathogens       Date:  2020-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.